UBS Group’s Park Ha Biological Technology Co BYAH Stock Holding History

UBS Group’s Portfolio BYAH Stock Details BYAH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10	Closed	-$84	–	11185
2026 Q1	$84	Buy	10 +1	+11%	+$31	﹤0.01%	10143
2025 Q4	$569	Sell	9 -4	-31%	-$485	﹤0.01%	9889
2025 Q3	$2.39K	Buy	13 +9	+225%	+$11.2K	﹤0.01%	9178
2025 Q2	$51.5K	Buy	+4	New	+$26.9K	﹤0.01%	7743
2025 Q1	–	Sell	-8	Closed	-$19.4K	–	10822
2024 Q4	$19.4K	Buy	+8	New	+$16.2K	﹤0.01%	7892

Other funds holding BYAH

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

CIAM

Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

UBS Group's BYAH Position: Q2 2026 in Review

UBS Group sold out of Park Ha Biological Technology Co (BYAH) in Q2 2026, closing a stake of 10 shares — an estimated $84 sold.

UBS Group first reported a position in BYAH in Q4 2024 and held it in 5 quarters. The position peaked at $51.5K in Q2 2025. 2 funds tracked by Wall St. Rank hold BYAH as of Q2 2026.

UBS Group reported no remaining Park Ha Biological Technology Co position as of Q2 2026 after selling out during the quarter.
UBS Group sold 10 Park Ha Biological Technology Co shares in Q2 2026, an estimated $84.
UBS Group first reported a position in Park Ha Biological Technology Co in Q4 2024 and held it in 5 quarters.
UBS Group's Park Ha Biological Technology Co position peaked at $51.5K in Q2 2025.
2 funds tracked by Wall St. Rank held Park Ha Biological Technology Co as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.